Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $115.3 million.

  • Protagonist Therapeutics' Non-Current Assets fell 930.38% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.1 million, marking a year-over-year increase of 17813.34%. This contributed to the annual value of $12.6 million for FY2024, which is 48664.5% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Non-Current Assets stood at $115.3 million, which was down 930.38% from $115.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Non-Current Assets registered a high of $136.3 million during Q1 2025, and its lowest value of $1.7 million during Q1 2024.
  • Over the past 5 years, Protagonist Therapeutics' median Non-Current Assets value was $7.0 million (recorded in 2021), while the average stood at $36.2 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 8778.36% in 2022, then skyrocketed by 780899.59% in 2025.
  • Protagonist Therapeutics' Non-Current Assets (Quarter) stood at $7.0 million in 2021, then crashed by 33.52% to $4.6 million in 2022, then tumbled by 53.55% to $2.1 million in 2023, then soared by 486.64% to $12.6 million in 2024, then soared by 814.29% to $115.3 million in 2025.
  • Its last three reported values are $115.3 million in Q3 2025, $115.5 million for Q2 2025, and $136.3 million during Q1 2025.